2/5/16 - U.S. FDA Approves Expanded Use of Bristol-Myers Squibbâ??s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Press/Media: Press / Media

PeriodFeb 6 2016

Media coverage

1

Media coverage

  • Title2/5/16 - U.S. FDA Approves Expanded Use of Bristol-Myers Squibbâ??s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletPharmacy Choice
    CountryUnited States
    Date2/6/16
    PersonsFred Poordad
View all 1
View less